Physician profile
Robert J Ruskiewicz
NPI 1639185564
$3,846.97
in general payments reported to CMS, 2019-2025
18 companies · $730 in 2025
The $730 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $403 · 2021: $297 · 2022: $574 · 2023: $790 · 2024: $801 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.92 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $641.17 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $607.36 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $434.33 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $427.78 | 2021-2025 | Vraylar |
| Lundbeck LLC | $401.89 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $267.81 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $229.20 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.40 | 2020-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $171.00 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $85.67 | 2023-2025 | Auvelity |
| Allergan, INC. | $85.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.15 | 2021-2023 | Trintellix |
| Indivior INC. | $64.03 | 2022-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $58.38 | 2024-2025 | Fanapt |
| Noven Therapeutics, LLC | $27.30 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $25.52 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.47 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ruskiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.